Yu, Kuo-Ming
Yang, Ping
Huang, Tien-Yu
Shen, Thomas Yen-Shih
Lau, Johnson Yiu-Nam
Hu, Oliver Yoa-Pu
Funding for this research was provided by:
Jacob Biotech Ltd
Avalon HepaPOC Ltd
Article History
Received: 15 February 2022
Revised: 27 March 2022
Accepted: 29 March 2022
First Online: 7 May 2022
Declarations
:
: Blood samples were collected from clinical participants undergoing GSP test performed in the Tri-Service General Hospital, Taipei, Taiwan (ClinicalTrials.gov: NCT03457311, registered on March 7, 2018). The protocol was approved by the Institutional Review Board of the Tri-Service General Hospital. Written informed consent was obtained from all participants, and the trial was conducted in accordance with the Declaration of Helsinki and under good clinical practice.
: Avalon HepaPOC Limited owns the intellectual property rights of this technology, and J. Y-N. Lau and O. Y-P. Hu are shareholders of this entity. No conflict of interest has been declared by the other coauthors.